RDHL
RedHill Biopharma Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$0.39
−6.91%Next report
Analyst consensus
- Next report date
- Mar 18, 2027
- EPS estimate
- -$474
- Revenue estimate
- $24.5M
Latest reported
- Last report date
- Sep 5, 2025
- EPS actual
- -$1.15
- EPS estimate
- —
- Revenue actual
- $2.0M
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -140.6%
- Revenue beats (12Q)
- 0
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Sep 5, 2025 | — | -$1.15 | — | $2.0M |
| Oct 3, 2024 | — | $900 | — | — |
| Aug 29, 2024 | -$30 | -$200 | Miss -566.67% | — |
| Jun 30, 2023 | — | $4.83 | — | $1.8M |
| Sep 23, 2022 | — | -$10 | — | $18.3M |
| Jun 23, 2022 | -$4.00 | -$3.00 | Beat 25.00% | $18.2M |
| Mar 17, 2022 | -$4.00 | -$5.00 | Miss -25.00% | $22.1M |
| Nov 30, 2021 | -$4.80 | -$4.60 | Beat 4.17% | $21.6M |
| Aug 26, 2021 | -$4.00 | -$6.20 | Miss -55.00% | $21.5M |
| May 27, 2021 | -$4.60 | -$5.30 | Miss -15.22% | $20.6M |
| Mar 18, 2021 | -$4.50 | -$7.00 | Miss -55.56% | $21.5M |
| Nov 12, 2020 | -$2.20 | -$5.00 | Miss -127.27% | $20.9M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Mar 18, 2027